The DOI matches its Crossref record.
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Abstract
OBJECTIVE: NIDDM occurs commonly among women with polycystic ovary syndrome (PCOS). The prevalence and natural history of its precursor, impaired glucose tolerance (IGT), is less well known. The objective of this study was to characterize the prevalence and incidence of glucose intolerance in a large cohort of women with well-characterized PCOS. RESEARCH DESIGN AND METHODS: A total of 122 women with clinical and hormonal evidence of PCOS were recruited from the Medicine, Endocrinology, Gynecology, and Pediatrics Clinics at the University of Chicago. All women had a standard oral glucose tolerance test (OGTT) with measurement of glucose and insulin levels. A subset of 25 women were subsequently restudied with the aim of characterizing the natural history of glucose tolerance in PCOS. RESULTS: Glucose tolerance was abnormal in 55 (45%) of the 122 women: 43 (35%) had IGT and 12 (10%) had NIDDM at the time of initial study. The women with NIDDM differed from those with normal glucose tolerance in that they had a 2.6-fold higher prevalence of first-degree relatives with NIDDM (83 vs. 31%, P < 0.01 by chi 2) and were significantly more obese (BMI 41.0 +/- 2.4 vs. 33.4 +/- 1.1 kg/m2, P < 0.01). For the entire cohort of 122 women, there was a significant correlation between fasting and 2-h glucose concentrations (r = 0.76, P < 0.0001); among the subset with IGT, the fasting glucose concentration was poorly predictive of the 2-h level (r = 0.25, NS). After a mean follow-up of 2.4 +/- 0.3 years (range 0.5-6.3), 25 women had a second OGTT. The glucose concentration at 2 h during the second glucose tolerance test was significantly higher than the 2-h concentration during the first study (161 +/- 9 vs. 139 +/- 6 mg/dl, P < 0.02). CONCLUSIONS: The prevalence of IGT and NIDDM in women with PCOS is substantially higher than expected when compared with age- and weight-matched populations of women without PCOS. The conversion from IGT to NIDDM is accelerated in PCOS. The fasting glucose concentration does not reliably predict the glucose concentration at 2 h after an oral glucose challenge, particularly among those with IGT, the subgroup at highest risk for subsequent development of NIDDM. We conclude that women with PCOS should periodically have an OGTT and must be closely monitored for deterioration in glucose tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In women with PCOS, dysglycemia typically consists of impaired glucose tolerance [12], its prevalence being of almost 30% in both adult women [13] and affected adolescents [14].”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [13]
In the citing paper
“Earlier-onset hyperglycaemia and rapid progression to DM2 is also reported in PCOS. 104,105”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [104]
Citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Brown adipose tissue transplantation ameliorates polycystic ovary syndrome
Yuan, X., Hu, T., Zhao, H., Huang, Y., Ye, R., Lin, J., Zhang, C., Zhang, H., Wei, G., Zhou, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523236113 · Cited by 203
“Accumulating evidence indicates that insulin resistance is one of the most common clinical features in PCOS (20) and that insulin resistance is often accompanied with reduced BAT activity (21).”
BackgroundRubin, K. H., Glintborg, D., Nybo, M., Abrahamsen, B., & Andersen, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01354 · Cited by 195
Type 2 Diabetes in Children: Clinical Aspects and Risk Factors
Arslanian, S. A. (2002) · Hormone Research in Paediatrics · doi:10.1159/000053308 · Cited by 201
Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome
Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0680-5 · Cited by 200
“The pathogenesis of PCOS includes insulin resistance and low grade inflammation [2], and women with PCOS have increased risk of metabolic syndrome [3, 4].”
BackgroundPapaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197
“Many investigators have focused both on impaired glucose tolerance, which affects 30%–40% of patients with PCOS (3), and on insulin resistance, which is present in a significant proportion of women with PCOS.”
BackgroundRetractedThe management of patients with polycystic ovary syndrome
Jayasena, C. N., & Franks, S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.102 · Cited by 196
Yıldırım, B., Sabir, N., & Kaleli̇, B. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00265-6 · Cited by 195
Young Obese Women with Polycystic Ovary Syndrome Have Evidence of Early Coronary Atherosclerosis
Juran, R., Kerchner, A., Maifeld, M., van Beek, E. J. R., Jagasia, D. H., & Dokras, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1343 · Cited by 194
The metabolic syndrome in polycystic ovary syndrome
Essah, P. A., & Nestler, J. E. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03345554 · Cited by 194
Mani, H., Levy, M. J., Davies, M. J., Morris, D. H., Gray, L. J., Bankart, J., Blackledge, H., Khunti, K. K., & Howlett, T. A. (2012) · Clinical Endocrinology · doi:10.1111/cen.12068 · Cited by 192
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. E. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 220
“It is also associated with several long-term health consequences, including obesity (18, 19), infertility (20), obstetric complications (21), type 2 diabetes (22, 23, 24), cardiovascular disease (24, 25, 26, 27), psychological distress (28) and ostensibly mood disorders (29, 30).”
Yaralı́, H., Yı́ldı́rı́r, A., Aybar, F., Kabakçı, G., Bükülmez, O., Akgül, E., & Oto, A. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01937-9 · Cited by 188
Nandi, A. A., Chen, Z., Patel, R., & Poretsky, L. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.003 · Cited by 189
Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction
Papaleo, E., Unfer, V., Baillargeon, J., Santis, L. D., Fusi, F., Brigante, C., Marelli, G., Cino, I., Redaelli, A., & Ferrari, A. G. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701672405 · Cited by 188
“Recently, many investigators have focused on the impaired glucose tolerance that affects 30–40% of patients with PCOS [3].”
BackgroundThe polycystic ovary syndrome per se is not associated with increased chronic inflammation
Möhlig, M., Spranger, J., Osterhoff, M., Ristow, M., Pfeiffer, A. F. H., Schill, T., Schlößer, H. W., Brabant, G. E., & Schöfl, C. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500525 · Cited by 180
Basic Infertility Including Polycystic Ovary Syndrome
Brassard, M., Ainmelk, Y., & Baillargeon, J. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2008.04.008 · Cited by 189
“In a study of 122 obese women with PCOS, 45% had either impaired glucose tolerance (35%) or T2D (10%) [130].”
BackgroundIncreased levels of serum advanced glycation end‐products in women with polycystic ovary syndrome
Diamanti‐Kandarakis, E., Piperi, C., Kalofoutis, A., & Creatsas, G. C. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02170.x · Cited by 179
Metformin administration improves endothelial function in women with polycystic ovary syndrome
Diamanti‐Kandarakis, E., Alexandraki, K., Protogerou, A. D., Piperi, C., Papamichael, C. M., Aessopos, A., Lekakis, J., & Mavrikakis, M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01910 · Cited by 179
The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome
Kakoly, N. S., Earnest, A., Teede, H. J., Moran, L. J., & Joham, A. E. (2019) · Diabetes Care · doi:10.2337/dc18-1738 · Cited by 174
“Previous studies have been inconclusive about the independent effect of PCOS on type 2 diabetes, with methodological limitations including small sample sizes (8,9,11), use of”
Mather, K. J., Kwan, F., & Corenblum, B. (2000) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00468-9 · Cited by 177
Nonalcoholic fatty liver disease and polycystic ovary syndrome
Vassilatou, E. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8351 · Cited by 176
Cruz, M. L., Shaibi, G. Q., Weigensberg, M. J., Spruijt‐Metz, D., Ball, G. D. C., & Goran, M. I. (2005) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.25.050304.092625 · Cited by 183
“Women with PCOS have increased incidence of other comorbidities including prediabetes, type 2 diabetes, hypertension, and dyslipidemia (46, 190).”
BackgroundNeuroendocrine dysfunction in polycystic ovary syndrome
Burt Solorzano, C. M., Beller, J. P., Abshire, M. Y., Collins, J. S., McCartney, C. R., & Marshall, J. C. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.007 · Cited by 173
Diamanti‐Kandarakis, E., Katsikis, I., Piperi, C., Kandaraki, E., Piouka, A., Papavassiliou, A. G., & Panidis, D. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03247.x · Cited by 172
Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome
Cinar, N., Kizilarslanoglu, M. C., Harmanci, A., Aksoy, D. Y., Bozdag, G., Demir, B., & Yildiz, B. O. (2011) · Human Reproduction · doi:10.1093/humrep/der338 · Cited by 168
Diagnostic criteria for polycystic ovary syndrome: A reappraisal
Azziz, R. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.01.085 · Cited by 172
Vryonidou, A., Papatheodorou, A., Tavridou, A., Terzi, T., Loi, V., Vatalas, I.-A., Batakis, N., Phenekos, C., & Dionyssiou-Asteriou, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2363 · Cited by 171
Pasquali, R., & Gambineri, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.014 · Cited by 170
Diamanti‐Kandarakis, E., Baillargeon, J., Iuorno, M. J., Jakubowicz, D. J., & Nestler, J. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021528 · Cited by 172
Prevalence of polycystic ovary syndrome in adolescents
Christensen, S. B., Black, M. H., Smith, N., Martinez, M. M., Jacobsen, S. J., Porter, A. H., & Koebnick, C. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.04.001 · Cited by 168
Variants inDENND1AAre Associated with Polycystic Ovary Syndrome in Women of European Ancestry
Welt, C. K., Styrkársdóttir, U., Ehrmann, D. A., Þorleifsson, G., Arason, G., Guðmundsson, J. A., Ober, C., Rosenfield, R. L., Saxena, R., Þorsteinsdóttir, U., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3478 · Cited by 170
Self-citationInflammatory and endothelial markers in women with polycystic ovary syndrome
Diamanti‐Kandarakis, E., Alexandraki, K., Piperi, C., Protogerou, A. D., Katsikis, I., Paterakis, T., Lekakis, J., & Panidis, D. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01712.x · Cited by 168
Metabolic complications of obesity in childhood and adolescence: more than just diabetes
Nathan, B. M., & Moran, A. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f43d19 · Cited by 174
Glucose Intolerance in a Large Cohort of Mediterranean Women With Polycystic Ovary Syndrome
Gambineri, A., Pelusi, C., Manicardi, E., Vicennati, V., Cacciari, M., Morselli‐Labate, A. M., Pagotto, U., & Pasquali, R. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2353 · Cited by 163
“Indeed, when considered separately, a positive family history for diabetes was present in all diabetic women and in approximately half of those presenting with IGT, making these results similar to those reported in other studies (5,6).”
Enhanced Mitogenic Signaling in Skeletal Muscle of Women With Polycystic Ovary Syndrome
Corbould, A. M., Zhao, H., Mirzoeva, S., Aird, F., & Dunaif, A. E. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-0453 · Cited by 166
“Polycystic ovary syndrome (PCOS), a common endocrinopathy characterized by disordered gonadotropin secretion and increased androgen production (1), is a leading risk factor for type 2 diabetes in premenopausal women (2,3).”
BackgroundComorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews
Gilbert, E. W., Tay, C. T., Hiam, D. S., Teede, H. J., & Moran, L. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13828 · Cited by 166
Ollila, M.-M. E., West, S., Keinänen-Kiukaanniemi, S., Jokelainen, J., Auvinen, J., Puukka, K., Ruokonen, A., Järvelin, M.-R., Tapanainen, J. S., Franks, S., et al. (2017) · Human Reproduction · doi:10.1093/humrep/dew329 · Cited by 165
“Reasons for discrepancy between the results might be the crosssectional design of studies (Ehrmann et al., 1999; Stepto et al., 2013; Joham et al., 2014) and the use of self-reported diagnosis of T2DM in the prospective ones (Elting et al., 2001; Boudreaux et al., 2006).”
ResultInfluentialBalen, A. H., & Anderson, R. A. (2007) · Human Fertility · doi:10.1080/14647270701731290 · Cited by 169
“Fasting glucose levels alone are poorly predictive of 2 h levels in impaired glucose tolerance, suggesting that a full OGTT should be conducted (Ehrmann et al., 1999).”
BackgroundCombined oral contraceptives in the treatment of polycystic ovary syndrome
Vrbíková, J., & Cibula, D. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi005 · Cited by 166
“ance to IGT or to DM 2 was described by two groups (Ehrmann et al., 1999; Wang and Norman, 2004), but both studies have a high number of drop-outs (80 and 50%), and so it is difficult to draw any definite conclusion.”
BackgroundInfluentialAgarwal, N., Rice, S., Bolusani, H., Luzio, S. D., Dunseath, G. J., Ludgate, M., & Rees, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1985 · Cited by 162
Maciel, G. A. R., Soares, J. M., Motta, E. L. A., Haidar, M. A., de Lima, G. R., & Baracat, E. C. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.08.012 · Cited by 161
“The exclusion criteria included the presence of [1] Cushing’s syndrome, [2] late-onset 21-hydroxylase deficiency, [3] thyroid dysfunction, [4] hyperprolactinemia, [5] androgen-secreting tumors, [6] diabetes mellitus, or [7] evidence of chronic renal or hepatic disease.”
BackgroundPolycystic ovary syndrome, adipose tissue and metabolic syndrome
Delitala, A. P., Capobianco, G., Delitala, G., Cherchi, P. L., & Dessole, S. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4429-2 · Cited by 159
Glintborg, D., & Andersen, M. (2009) · Gynecological Endocrinology · doi:10.3109/09513590903247873 · Cited by 166
“Previous studies showed that increased hsCRP is the strongest univariate predictor for the risk of cardiovascular events [59].”
BackgroundInfluentialMetabolic effects of obesity on reproduction
Pasquali, R., & Gambineri, A. (2006) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61179-0 · Cited by 159
Serum adiponectin levels in women with polycystic ovary syndrome
Panidis, D. (2003) · Human Reproduction · doi:10.1093/humrep/deg353 · Cited by 156
“(Ehrmann et al., 1999), as well as cardiovascular disease (Futterweit, 1999).”
BackgroundNonalcoholic Fatty Liver Disease in Women
Suzuki, A., & Abdelmalek, M. F. (2009) · Women s Health · doi:10.2217/17455057.5.2.191 · Cited by 157
“Insulin resistance has been demonstrated in both obese and nonobese women with PCOS [66].”
BackgroundPolycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review
Harris, H. R., & Terry, K. L. (2016) · Fertility Research and Practice · doi:10.1186/s40738-016-0029-2 · Cited by 155
“In addition, women with PCOS are at increased risk of type II diabetes [20, 21], insulin resistance, and metabolic syndrome [15–19].”
BackgroundErnst, C. L., & Goldberg, J. F. (2002) · PubMed · Cited by 156
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154
“Many investigators have focused both on impaired glucose tolerance, which affects 30– 40% of patients with PCOS [6], and on insulin resistance, which is present in a significant proportion of women with PCOS.”
BackgroundGlintborg, D., Hass Rubin, K., Nybo, M., Abrahamsen, B., & Andersen, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1108 · Cited by 154
Prevalence of Polycystic Ovary Syndrome and Related Disorders in Mexican Women
Morán, C., Tena, G., Morán, S., Ruiz, P., Reyna, R., & Duque, X. (2010) · Gynecologic and Obstetric Investigation · doi:10.1159/000277640 · Cited by 152
“PCOS patients have a high risk of developing chronic disorders, such as impaired glucose tolerance and type 2 diabetes mellitus [ ,”
BackgroundEarly Metabolic Derangements in Daughters of Women with Polycystic Ovary Syndrome
Sir‐Petermann, T., Maliqueo, M. A., Ethel Codner, D., Echiburú, B., Crisosto, N., Pérez, V., Pérez‐Bravo, F., & CASSORLA, F. G. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1036 · Cited by 151
MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease
Schiffer, L., Kempegowda, P., Arlt, W., & O’Reilly, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0124 · Cited by 162
Prevalence of Polycystic Ovary Syndrome Among Premenopausal Women With Type 2 Diabetes
Peppard, H. R., Marfori, J., Iuorno, M. J., & Nestler, J. E. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1050 · Cited by 147
“It has also been reported that the rate of conversion from impaired glucose tolerance to type 2 diabetes is increased 5- to 10-fold in women with PCOS (6).”
BackgroundUse of metformin in polycystic ovary syndrome
Mathur, R., Alexander, C. J., Yano, J., Trivax, B., & Azziz, R. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.09.010 · Cited by 150
A Review of the Relationships Between Extreme Obesity, Quality of Life, and Sexual Function
Sarwer, D. B., Lavery, M. E., & Spitzer, J. C. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0588-1 · Cited by 144
“More specifically, excess body weight is associated with several correlates of infertility, including amenorrhea, irregular menstrual cycles, increased levels of androgen, polycystic ovarian syndrome (PCOS), decreased rates of pregnancy following fertility treatments, increased risk of miscarriage, and poorer outcomes…”
BackgroundInfluentialPolycystic Ovary Syndrome in Adolescence
Buggs, C., & Rosenfield, R. L. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.04.005 · Cited by 147
“Although a direct link between PCOS and cardiovascular events has not been established [39], the evidence that PCOS is associated with metabolic syndrome and T2DM is undeniable, with a consequent relative risk of cardio- and cerebrovascular morbidity approximating 1.5 [40].”
BackgroundInfluentialSelf-citationZhang, H., Zhu, F., Xiong, J., Shi, X., & Fu, S. (2009) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2009.02347.x · Cited by 139
Risk of T2DM and impaired fasting glucose among pcos subjects: Results of an 8-year follow-up
Boudreaux, M. Y., Talbott, E. O., Kip, K. E., Brooks, M. M., & Witchel, S. F. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0056-1 · Cited by 139
“Incidence rates of T2DM in two prior studies were 9% [ 17 ] and 16% [18••] among women with PCOS at baseline, regardless of basal glucose tolerance.”
BackgroundResultTrikudanathan, S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.09.003 · Cited by 140
Adiponectin protects against development of metabolic disturbances in a PCOS mouse model
Benrick, A., Chanclón, B., Micallef, P., Wu, Y., Hadi, L., Shelton, J. M., Stener‐Victorin, E., & Asterholm, I. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708854114 · Cited by 140
“Indeed, it has been demonstrated that 30–40% of women with PCOS have impaired glucose tolerance, and as many as 10% develop diabetes by the age of 40 y (3, 4).”
BackgroundAnti-Mullerian Hormone Levels in Peripubertal Daughters of Women with Polycystic Ovary Syndrome
Crisosto, N., Ethel Codner, D., Maliqueo, M. A., Echiburú, B., Sánchez, F., CASSORLA, F. G., & Sir‐Petermann, T. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0267 · Cited by 138
Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome
Pal, L., Berry, A., Coraluzzi, L., Kustan, E., Danton, C., Shaw, J., & Taylor, H. S. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.696753 · Cited by 137
Ducluzeau, P., Cousin, P., Malvoisin, E., Bornet, H., Vidal, H., Laville, M., & PUGEAT, M. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030219 · Cited by 137
Diamanti‐Kandarakis, E. (2006) · Endocrine · doi:10.1385/endo:30:1:13 · Cited by 137
Goverde, A. J., van Koert, A. J. B., Eijkemans, M. J., Knauff, E. A. H., Westerveld, H. E., Fauser, B. C. J. M., & Broekmans, F. J. (2008) · Human Reproduction · doi:10.1093/humrep/den433 · Cited by 135
Effects of lifestyle modification in polycystic ovarian syndrome
Moran, L., Brinkworth, G. D., Noakes, M., & Norman, R. J. (2006) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61182-0 · Cited by 136
Effects of Exercise and Nutritional Counseling in Women with Polycystic Ovary Syndrome
Bruner, B., Chad, K., & Chizen, D. (2006) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h06-007 · Cited by 133
“Currently, polycystic ovary syndrome (PCOS) is described as the most frequent cause of anovulation resulting in infertility in adult women (Knochenhauer et al. 1998; Ehrmann et al. 1999; Sozen and Arici 2000).”
BackgroundResultRelationships between Sleep Disordered Breathing and Glucose Metabolism in Polycystic Ovary Syndrome
Tasali, E., Cauter, E. V., & Ehrmann, D. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1084 · Cited by 136
Self-citationGlintborg, D., Andersen, M., Hagen, C., Frystyk, J., Hulstrøm, V., Flyvbjerg, A., & Hermann, A. P. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02207 · Cited by 133
Spranger, J., Möhlig, M., Wegewitz, U. E., Ristow, M., Pfeiffer, A. F. H., Schill, T., Schlösser, H. W., Brabant, G. E., & Schöfl, C. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02159.x · Cited by 130
“In addition, insulin resistance and the associated hyperinsulinaemia might be central to the high risk for impaired glucose tolerance and type 2 diabetes mellitus, as well as atherosclerosis and cardiovascular disease observed in PCOS women (Conway et al., 1992; Guzick et al., 1996; Birdsall et al., 1997; Ehrmann et a…”
BackgroundColilla, S., Cox, N. J., & Ehrmann, D. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7518 · Cited by 130
“Serum insulin was assayed by a double antibody technique (4) with a lower limit of sensitivity of 20 pmol/L and an average intraassay coefficient of variation of 6%.”
BackgroundMethodSelf-citationSequeira, I. R., Lentle, R. G., Kruger, M. C., & Hurst, R. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099256 · Cited by 128
“Graphic comparison of integrated half-hourly glucose levels from fifteen subjects with non-insulin dependent diabetes mellitus [44] with those of half-hourly mannitol excretion obtained from our study, showed that both peaked at approximately two hours T a b le 1 .”
BackgroundMethodResultInfluentialRandomized Placebo-Controlled Trial of Metformin for Adolescents With Polycystic Ovary Syndrome
Bridger, T., MacDonald, S., Baltzer, F., & Rodd, C. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.3.241 · Cited by 126
“Once thought to be purely a cosmetic and fertility problem, it is now known that women with PCOS have increased risk factors for cardiovascular disease and are at risk of developing diabetes.(7-9) Although the pathogenesis is not fully understood, evidence suggests insulin resistance and hyperinsulinemia play a key pa…”
BackgroundMetabolic Profile in Sons of Women with Polycystic Ovary Syndrome
Recabarren, S. E., Smith, R., Ríos, R., Maliqueo, M. A., Echiburú, B., Ethel Codner, D., CASSORLA, F. G., Rojas, P., & Sir‐Petermann, T. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2256 · Cited by 126
The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review
Krul-Poel, Y. H. M., Snackey, C., Louwers, Y. V., Lips, P. T. A. M., Lambalk, C. B., Laven, J. S. E., & Şimşek, S. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0617 · Cited by 124
Bird, S. T., Hartzema, A. G., Brophy, J. M., Etminan, M., & Delaney, J. A. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.120677 · Cited by 126
“Women with a claim for PCOS (ICD-9-CM 256.4), a claim for a diagnostic criteria (anovulation [ICD-9-CM 628.0] and hirsutism [ICD-9-CM 704.1]), or a prescription for antiandrogen treatment (i.e., spironolactone) were included as having PCOS.”
ResultInfluentialThe genetics of polycystic ovary syndrome
Amato, P., & Simpson, J. L. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2004.05.002 · Cited by 122
Glintborg, D., Henriksen, J. E., Andersen, M., Hagen, C., Hangaard, J., Rasmussen, P. E., Schousboe, K., & Hermann, A. P. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.06.040 · Cited by 126
Tasali, E., Chapotot, F., Leproult, R., Whitmore, H. R., & Ehrmann, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1187 · Cited by 127
“PCOS women face lifelong risk of cardiometabolic disease with nearly half developing type 2 diabetes before the end of their fourth decade of life (5, 6).”
Self-citationChan, C. C. W., Koo, M. W. L., Ng, E. H. Y., Tang, O., Yeung, W. S. B., & Ho, P. (2005) · Journal of the Society for Gynecologic Investigation · doi:10.1016/j.jsgi.2005.10.006 · Cited by 124
Insulin resistance and polycystic ovary syndrome
Galluzzo, A., Amato, M. C., & Giordano, C. S. D. S. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.05.004 · Cited by 122
Criteria for Polycystic Ovarian Morphology in Polycystic Ovary Syndrome as a Function of Age
Alsamarai, S., Adams, J. M., Murphy, M. K., Post, M. D., Hayden, D. L., Hall, J. E., & Welt, C. K. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0839 · Cited by 122
Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth
Diamanti-Kandarakis, E., & Piperi, C. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi025 · Cited by 167
“IRS2, no association Ehrmann et al. (2002a), Ibanez et al.”
Weerakiet, S., Srisombut, C., Bunnag, P., Sangtong, S., Chuangsoongnoen, N., & Rojanasakul, A. (2001) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(01)00477-5 · Cited by 119
Use of clomiphene citrate in infertile women: a committee opinion
(2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.05.033 · Cited by 124
Relationship of Adolescent Polycystic Ovary Syndrome to Parental Metabolic Syndrome
Leibel, N. I., Baumann, E. E., Kocherginsky, M., & Rosenfield, R. L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1707 · Cited by 118
Self-citationThe effects of old, new and emerging medicines on metabolic aberrations in PCOS
Bargiota, Α., & Diamanti‐Kandarakis, E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812437355 · Cited by 120
Cardiovascular Risk in Women With PCOS
Scicchitano, P., Dentamaro, I., Carbonara, R., Bulzis, G., Dachille, A., Caputo, P., Riccardi, R., Locorotondo, M., Mandurino, C., & Ciccone, M. M. (2012) · Intern J Endocrinol Metab · doi:10.5812/ijem.4020 · Cited by 117
Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A. (2015) · Hormones · doi:10.1007/bf03401383 · Cited by 117
Morgan, C. L., Jenkins-Jones, S., Currie, C. J., & Rees, D. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1690 · Cited by 136
“(9) found a significantly higher 2-h glucose value during a second oral glucose tolerance test than in the first.”
BackgroundInfluentialOn the Association Between Valproate and Polycystic Ovary Syndrome
Genton, P., Bauer, J. M., Duncan, S., Taylor, A. E., Balen, A. H., Eberle, A., Pedersen, B., Salas‐Puig, X., & Sauer, M. V. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.28899.x · Cited by 114
“Recent studies demonstrate that 7–10% of women with PCOS have type 2 diabetes and that an additional 30% have impaired glucose tolerance, far above the rates expected for their age (43,44).”
BackgroundMather, K. J., Verma, S., Corenblum, B., & Anderson, T. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6587 · Cited by 123
The Metabolic Syndrome in Polycystic Ovary Syndrome
Essah, P. A., Wickham, E. P., & Nestler, J. E. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31802f3547 · Cited by 113
“Data from the US and Australia suggest the conversion rate from impaired glucose tolerance to frank diabetes is 5- to 10-fold higher among women with PCOS.(12,35) Converse to evidence that women with PCOS have a high risk of type 2 diabetes, studies have also revealed that a higher prevalence of PCOS is present among…”
BackgroundInsulin-sensitizing agents in polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02156 · Cited by 112
Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome
Chen, X., Yang, D., Li, L., Feng, S., & Wang, L. (2006) · Human Reproduction · doi:10.1093/humrep/del142 · Cited by 112
“This result was similar to other studies, which showed that FPG was a poor predictor of abnormal glucose tolerance in women with PCOS (Ehrmann et al., 1999; Legro et al., 1999; Arslanian et al., 2001).”
BackgroundResultInfluentialGoodman, N. F., Bledsoe, M. B., Cobin, R. H., Futterweit, W., Goldzieher, J. W., Petak, S. M., Smith, K. D., Steinberger, E., Anderson, R. J., Bergman, D. A., et al. (2001) · Endocrine Practice · doi:10.4158/ep.7.2.120 · Cited by 111
An association between non‐alcoholic fatty liver disease and polycystic ovarian syndrome
Brzozowska, M. M., Ostapowicz, G., & Weltman, M. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05740.x · Cited by 110
Tasali, E., Van Cauter, E., Hoffman, L., & Ehrmann, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0925 · Cited by 111
Self-citationEscobar-Morreale, H. F., Samino, S., Insenser, M. R., Vinaixa, M., Luque‐Ramírez, M., Lasunción, M. A., & Correig, X. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.176396 · Cited by 109
Metadata
- Authors
- Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J.
- Affiliations
- University of Chicago (US)
- ORCID
- Rosenfield, R L
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1999-01-01
- Volume
- 22
- Issue
- 1
- Pages
- 141-146
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2007816906
- Cited by
- 1,257
- References
- 0
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 22 · 2023: 18 · 2022: 39 · 2021: 45 · 2020: 32 · 2019: 39 · 2018: 40 · 2017: 45 · 2016: 37 · 2015: 63 · 2014: 63 · 2013: 55 · 2012: 75
- FWCI
- 31.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- polycystic ovary syndrome, impaired glucose tolerance, type 2 diabetes, prevalence, incidence, natural history (disease), oral glucose tolerance test, fasting blood glucose, obesity, family history of diabetes, women's health
- MeSH terms
- Adult, Analysis of Variance, Blood Glucose, Chicago, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glucose Tolerance Test, Humans, Insulin, Polycystic Ovary Syndrome, Regression Analysis, Testosterone, Prevalence, Glucose Intolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
